Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $4.2
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and raises the price target from $3.2 to $4.2.
Canaccord Genuity analyst Richard Close maintains Clover Health Investments (NASDAQ:CLOV) with a Buy and raises the price target from $3.2 to $4.2.